The results of this study have a significant reference value for the prognosis research of AQP4-related glioma patients, and have indicated that AQP4 could be considered as a potential new early biomarker of glioma progression (Frigeri et al., 2007; Du et al., 2020; Valente et al., 2022). The gene discussed is AQP4; the disease is central nervous system cancer.